CoChat

Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers

Open access
Rubinson, Douglas A., Tanaka, Noritaka, Fece de la Cruz, Ferran, Kapner, Kevin S., Rosenthal, Michael H., Norden, Bryanna L., Barnes, Haley, Ehnstrom, Sara, Morales-Giron, Alvin A., Brais, Lauren K., Lemke, Christopher T., Aguirre, Andrew J., Corcoran, Ryan B. · 2024 · Cancer Discovery
Cited by 43

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors. Significance: These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors. See related commentary by Seale and Misale, p. 698. This article is featured in Selected Articles from This Issue, p. 695

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-1138

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 43

Metadata

Authors
Rubinson, D. A., Tanaka, N., Fece de la Cruz, F., Kapner, K. S., Rosenthal, M. H., Norden, B. L., Barnes, H., Ehnstrom, S., Morales-Giron, A. A., Brais, L. K., Lemke, C. T., Aguirre, A. J., & Corcoran, R. B.
Venue
Cancer Discovery
Published
2024-01-18
Volume
14
Issue
5
Pages
727-736
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4390985936
Cited by
43
References
19
FWCI
5.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-23-1138
The paper
Rubinson, D. A., Tanaka, N., Fece de la Cruz, F., Kapner, K. S., Rosenthal, M. H., Norden, B. L., Barnes, H., Ehnstrom, S., Morales-Giron, A. A., Brais, L. K., Lemke, C. T., Aguirre, A. J., & Corcoran, R. B. (2024). Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-1138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.